How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

681 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

501. Cost-effectiveness of sibutramine in the treatment of obesity

Cost-effectiveness of sibutramine in the treatment of obesity Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

502. Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program

Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program Malone D C, Raebel M A, Porter J A, Lanty F (...) A, Conner D A, Gay E C, Merenich J A, Vogel E A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of sibutramine in conjunction with a weight management programme (WMP) for the treatment of overweight and obese individuals

2005 NHS Economic Evaluation Database.

503. Orlistat and sibutramine beyond weight loss

Orlistat and sibutramine beyond weight loss Orlistat and sibutramine beyond weight loss Orlistat and sibutramine beyond weight loss Mannucci E, Dicembrini I, Rotella F, Rotella C M CRD summary This review aimed to assess the effects of orlistat and sibutramine on blood lipids. It concluded that orlistat, but not sibutramine, determined a significant reduction in total cholesterol independent of the weight loss itself. Important information on the methods was missing from the review, so (...) it was impossible to determine whether the conclusions were reliable. Authors' objectives To assess the effects of orlistat and sibutramine on blood lipids independent of weight loss. Searching MEDLINE was searched from inception to the end of May 2005 for relevant English-language articles. Search terms were reported. The reference lists of identified trials and review articles were searched to identify further relevant evidence. Study selection Randomised, double-blind, placebo-controlled trials of six to 12

2008 DARE.

504. The efficacy and safety of sibutramine for weight loss: a systematic review

The efficacy and safety of sibutramine for weight loss: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

505. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies

Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies Vettor R, Serra R, Fabris R, Pagano C, Federspil G CRD summary This review assessed the effects of sibutramine on weight and glycaemic (...) control in obese patients with type 2 diabetes mellitus. The authors concluded that sibutramine may help to improve glycaemic control because it reduces weight. Inadequate reporting of the quality assessment, characteristics of the included studies, drop-outs and some review methods makes interpretation of the evidence difficult. Authors' objectives To assess the effects of sibutramine on weight and glycaemic control in obese people with type 2 diabetes mellitus. Searching The Cochrane Library

2005 DARE.

506. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany

Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany Brennan A, Ara R, Sterz R, Matiba B, Bergemann R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined a 1-year course of sibutramine in combination with diet and lifestyle advice for the treatment of obese patients. Sibutramine was initially given at a dosage of 10 mg/day but could be switched to 15 mg/day in the case of non-response at 1 or 3 months. Type

2006 NHS Economic Evaluation Database.

507. The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries

The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

508. Review: orlistat and sibutramine are modestly effective for weight loss at 1 year Full Text available with Trip Pro

Review: orlistat and sibutramine are modestly effective for weight loss at 1 year Review: orlistat and sibutramine are modestly effective for weight loss at 1 year | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: orlistat and sibutramine are modestly effective for weight loss at 1 year Article Text Therapeutics Review: orlistat and sibutramine are modestly effective for weight loss at 1 year Free Christopher D Byrne , FRCP

2006 Evidence-Based Medicine

509. Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Full Text available with Trip Pro

Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Article Text Therapeutics Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes Free Christopher

2006 Evidence-Based Medicine

510. A systematic review of the clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity Full Text available with Trip Pro

A systematic review of the clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from

2002 NIHR HTA programme

511. Review: dietary plus pharmacological intervention (orlistat or sibutramine) induces long term weight loss in overweight or obese adults

Review: dietary plus pharmacological intervention (orlistat or sibutramine) induces long term weight loss in overweight or obese adults Review: dietary plus pharmacological intervention (orlistat or sibutramine) induces long term weight loss in overweight or obese adults | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: dietary plus pharmacological intervention (orlistat or sibutramine) induces long term weight loss in overweight

2007 Evidence-Based Nursing

512. Sibutramine: a review of its contribution to the management of obesity

Sibutramine: a review of its contribution to the management of obesity Sibutramine: a review of its contribution to the management of obesity Sibutramine: a review of its contribution to the management of obesity McNeely W, Goa K L Authors' objectives To review the contribution of sibutramine to the management of obesity. Searching Medical literature published in any language since 1966 identified using AdisBase (a proprietary database of Adis International, Auckland, New Zealand), MEDLINE (...) and EMBASE. Search terms used on all databases were 'sibutramine' and 'obesity'. Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Study selection Study designs of evaluations included in the review Study designs reported in the review include double-blind, randomised controlled trials (RCTs). When available, large, well controlled trials

1998 DARE.

513. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment

The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G Authors' objectives To assess systematically the clinical effectiveness and cost (...) - effectiveness of sibutramine in the management of obesity. Searching Nineteen electronic databases were searched from inception to June 2000. These databases included MEDLINE, BIOSIS Previews, EMBASE, CINAHL and other topic-specific databases and citation indices. An extensive search strategy was reported in the appendices of the report. The authors also carried out Internet searches, checked the bibliographies of included papers for additional relevant studies, and received a submission of evidence from

2002 DARE.

514. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment

The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment. Health Technology Assessment 2002; 6(6): 1-97 Authors' objectives This review aims to assess systematically the clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity. Authors

2002 Health Technology Assessment (HTA) Database.

515. Guidance on the use of sibutramine for the treatment of obesity in adults

Guidance on the use of sibutramine for the treatment of obesity in adults Guidance on the use of sibutramine for the treatment of obesity in adults Guidance on the use of sibutramine for the treatment of obesity in adults National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence (...) . Guidance on the use of sibutramine for the treatment of obesity in adults. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 31. 2001 Authors' objectives To provide guidance on the use of sibutramine for the treatment of obesity in adults. Authors' conclusions Guidance 1.1 Sibutramine should be prescribed only as part of an overall treatment plan for management of nutritional obesity in people aged 18-65 years who meet one of the following criteria: 1.1.1 a body

2001 Health Technology Assessment (HTA) Database.

516. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. (Abstract)

Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Antiobesity treatment is recommended for selected patients in whom lifestyle modification is unsuccessful. Two antiobesity drugs are currently licensed for long-term use. Orlistat, a gastrointestinal lipase inhibitor, reduces weight by around 3 kg on average and decreases progression to diabetes in high-risk patients; adverse gastrointestinal effects are common. Sibutramine, a monoamine-reuptake inhibitor, results in mean

2007 Lancet

517. Is there any contraindication to sibutramine or orlistat in a female patient with mild porphyria variagata?

Is there any contraindication to sibutramine or orlistat in a female patient with mild porphyria variagata? Is there any contraindication to sibutramine or orlistat in a female patient with mild porphyria variagata? - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere (...) clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is there any contraindication to sibutramine or orlistat in a female patient with mild porphyria variagata? We have found nothing that states sibutramine or orlistat are contraindicated

2006 TRIP Answers

518. Is there any evidence to suggest that any of the antiobesity drugs (orlistat, sibutramine or rimomabant) are effective as sole intervention for weight loss ie without combined dietary and / or lifesty

Is there any evidence to suggest that any of the antiobesity drugs (orlistat, sibutramine or rimomabant) are effective as sole intervention for weight loss ie without combined dietary and / or lifesty Is there any evidence to suggest that any of the antiobesity drugs (orlistat, sibutramine or rimomabant) are effective as sole intervention for weight loss ie without combined dietary and / or lifestyle interventions? - Trip Database or use your Google+ account Turning Research Into Practice ALL (...) @tripdatabase.com Is there any evidence to suggest that any of the antiobesity drugs (orlistat, sibutramine or rimomabant) are effective as sole intervention for weight loss ie without combined dietary and / or lifestyle interventions? This question presented problems in the literature searching stage as as our usual information sources do not permit restricting to sole rather than combined interventions. It would appear from our literature search that these antiobesity drugs have generally be evaluated as part

2007 TRIP Answers

519. Is there any reason not to co-prescribe rimonabant and sibutramine for weight loss?

Is there any reason not to co-prescribe rimonabant and sibutramine for weight loss? Is there any reason not to co-prescribe rimonabant and sibutramine for weight loss? - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches (...) types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is there any reason not to co-prescribe rimonabant and sibutramine for weight loss? This is a question which we cannot answer with any confidence. We found no guidelines supporting this co-prescribing and we certainly

2007 TRIP Answers

520. Can sibutramine and orlistat be combined in severe cases of obesity?

Can sibutramine and orlistat be combined in severe cases of obesity? Can sibutramine and orlistat be combined in severe cases of obesity? - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top (...) information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Can sibutramine and orlistat be combined in severe cases of obesity? The CKS guideline on obesity considers the combination of sibutramine and orlistat and states: " There is evidence from one study to suggest that the addition of orlistat to sibutramine does

2008 TRIP Answers

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>